Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study
OncLive TV
Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit
Advertisement
Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma
Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test
Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size
Dr. David Cella from Northwestern University Feinberg School of Medicine on Quality of Life Assessments' Cost Effectiveness
Advertisement
Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test
Donna Berry on the Challenges Patients With Prostate Cancer Face
Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer
Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma
Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio
Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer
Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial
Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly
Dr. David Cella from Northwestern University Feinberg School of Medicine Explains the Increase in Quality of Life Assessments
Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells
Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research
Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results
Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results
Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab
Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects
Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial
Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial
Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results
Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early
Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC
Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial
Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab
Dr. Vogelzang From the Comprehensive Cancer Centers of Nevada on XL184's Effect on Bone Metastases.
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5